Chemistry:CUMYL-4CN-BINACA
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C22H24N4O |
| Molar mass | 360.461 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-4CN-BINACA (also known as CUMYL-CYBINACA or SGT-78) is an indazole-3-carboxamide based synthetic cannabinoid that has been sold online as a designer drug.[2][3][4][5][6][7] It is a potent agonist for cannabinoid receptors CB1 and CB2, with in vitro EC50 values of 0.58 nM and 6.12 nM, respectively.[8] In mice, CUMYL-4CN-BINACA produces hypothermic and pro-convulsant effects via the CB1 receptor,[8] and anecdotal reports suggest it has an active dose of around 0.1 mg in humans.[9]
CUMYL-4CN-BINACA is metabolized to produce cyanide, raising concerns about liver toxicity.[7] There is one reported case of hyperthermia, rhabdomyolysis, and kidney failure associated with its use.[10]
See also
- 4CN-AMB-BUTINACA
- 5F-CUMYL-PINACA
- 5F-SDB-006
- ADAMANTYL-THPINACA
- CUMYL-PICA
- CUMYL-PINACA
- CUMYL-THPINACA
- SDB-006
- NNE1
References
- ↑ "Substance Details CUMYL-4CN-BINACA". https://www.unodc.org/LSS/Substance/Details/c9a6b008-085a-4c8c-960a-ae1c3200ae25.
- ↑ "4-cyano CUMYL-BUTINACA". Cayman Chemical. https://www.caymanchem.com/product/20194.
- ↑ "Identification of the Synthetic Cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in Plant Material and Quantification in Post-Mortem Blood Samples". Journal of Analytical Toxicology 41 (9): 720–728. November 2017. doi:10.1002/dta.2248. PMID 28977413.
- ↑ "In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Drug Testing and Analysis 10 (1): 148–157. January 2018. doi:10.1002/dta.2298. PMID 28885775.
- ↑ "Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Forensic Science International 281: 98–105. December 2017. doi:10.1016/j.forsciint.2017.10.020. PMID 29125990.
- ↑ "Identification of the synthetic cannabinoid N-(2-phenyl-propan-2-yl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in a herbal mixture product". Forensic Toxicology 36 (1): 192–199. January 2018. doi:10.1007/s11419-017-0372-y. ISSN 1860-8965.
- ↑ 7.0 7.1 "Metabolism study for CUMYL-4CN-BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway". Drug Testing and Analysis 10 (8): 1270–1279. March 2018. doi:10.1002/dta.2373. PMID 29577658.
- ↑ 8.0 8.1 "CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist". Frontiers in Pharmacology 10: 595. 2019. doi:10.3389/fphar.2019.00595. PMID 31191320.
- ↑ "EMCDDA–Europol Joint Report on a new psychoactive substance: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide (CUMYL-4CN-BINACA)". http://www.emcdda.europa.eu/publications/joint-reports/cumyl-4cn-binaca_en.
- ↑ "A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis". Clinical Toxicology 57 (6): 421–422. June 2019. doi:10.1080/15563650.2018.1534241. PMID 30442067.
 |  |
